Literature DB >> 11493377

Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation.

M P Hoang1, V G Prieto, J L Burchette, C R Shea.   

Abstract

BACKGROUND: Recurrent melanocytic lesions may histologically resemble malignant melanoma.
METHODS: We evaluated the original nevi (ON) and recurrent nevi (RN) of 15 patients by routine histology and immunohistochemistry (IHC), examining expression of S-100 protein, gp100 (with HMB-45), MART-1, tyrosinase, and the Ki-67 proliferation marker.
RESULTS: Compared with ON, RN had a dermal scar, a significantly greater number of melanophages, and a greater extent of cellular atypia including prominent nucleoli and larger cell size. Architecturally, RN showed significantly less symmetry than ON; however, the percentage of junctional cohesive nests, the presence of suprabasal spread, and the degree of confluence were similar between ON and RN. Both ON and RN showed a decrease in expression of gp100 and tyrosinase with increasing depth ("maturation gradient") and low proliferative activity in both the junctional (4.6% for ON vs. 4.13% for RN) and the dermal components (0.93% for ON vs. 1.45% for RN).
CONCLUSIONS: RN exhibit a dermal scar, a greater number of melanophages, cytologic atypia, and asymmetry than ON, features that may raise concern about the possibility of malignant melanoma. However, the area with the irregular architectural pattern is restricted to the epidermis and dermis immediately above the scar. In addition, IHC helps to distinguish RN from malignant melanoma; specifically, RN demonstrate an immunohistochemical "maturation pattern" (with HMB-45 and anti-tyrosinase) and a low proliferative index (with Ki-67).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493377     DOI: 10.1034/j.1600-0560.2001.028008400.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

1.  High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.

Authors:  Szu-Ying Chin; Pei-Ru Wu; Yi-Hsien Shih; Chung-Min Yeh; Woan-Ruoh Lee; Shing-Chuan Shen; Kun-Tu Yeh; Ming-Chung Jiang; Jonathan Te-Peng Tseng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.

Authors:  Michael A Davies; Katherine Stemke-Hale; E Lin; Carmen Tellez; Wanleng Deng; Yennu N Gopal; Scott E Woodman; Tiffany C Calderone; Zhenlin Ju; Alexander J Lazar; Victor G Prieto; Kenneth Aldape; Gordon B Mills; Jeffrey E Gershenwald
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 3.  Recognizing Histopathological Simulators of Melanoma to Avoid Misdiagnosis.

Authors:  Sara Waqar; Sheeba George; Wilford Jean-Baptiste; Amina Yusuf Ali; Bithaiah Inyang; Feeba Sam Koshy; Kitty George; Prakar Poudel; Roopa Chalasani; Mastiyage R Goonathilake; Lubna Mohammed
Journal:  Cureus       Date:  2022-06-20

4.  [DNA copy number changes in the diagnosis of melanocytic tumors].

Authors:  J Bauer; B C Bastian
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 5.  Histologic mimics of malignant melanoma.

Authors:  Caroline Bsirini; Bruce R Smoller
Journal:  Singapore Med J       Date:  2018-05-18       Impact factor: 1.858

6.  Recurrent nevi: report of three cases with dermatoscopic-dermatopathologic correlation.

Authors:  Philipp Tschandl
Journal:  Dermatol Pract Concept       Date:  2013-01-31

7.  Sclerosing Melanocytic Lesions (sclerosing Melanomas with Nevoid Features and Sclerosing Nevi with Pseudomelanomatous Features) - An Analysis of 90 Lesions.

Authors:  Biljana Grcar-Kuzmanov; Emanuela Bostjancic; Juan Antonio Contreras Bandres; Joze Pizem
Journal:  Radiol Oncol       Date:  2018-01-24       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.